| scholarly article | Q13442814 |
| P50 | author | Philip F Halloran | Q40000948 |
| P2093 | author name string | Bruce Kaplan | |
| Gian S Jhangri | |||
| Banu Sis | |||
| Sakarn Bunnag | |||
| Kara Allanach | |||
| P2860 | cites work | Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause | Q43580802 |
| Identification of endothelial cell genes by combined database mining and microarray analysis | Q46979966 | ||
| Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. | Q53521493 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| endothelium | Q111140 | ||
| P304 | page(s) | 2312-2323 | |
| P577 | publication date | 2009-07-22 | |
| P1433 | published in | American Journal of Transplantation | Q4744273 |
| P1476 | title | Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. | |
| P478 | volume | 9 |
| Q48186622 | A Probabilistic Approach to Histologic Diagnosis of Antibody-Mediated Rejection in Kidney Transplant Biopsies |
| Q39869686 | A molecular classifier for predicting future graft loss in late kidney transplant biopsies |
| Q51432032 | A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. |
| Q47578423 | A significant role for anti-human leukocyte antigen antibodies and antibody-mediated rejection in the biopsy-for-cause population. |
| Q40331013 | AST Cutting Edge of Transplantation 2013 Meeting Report: a comprehensive look at B cells and antibodies in transplantation |
| Q39826008 | Acute Antibody-Mediated Rejection in Kidney Transplant Based on the 2013 Banff Criteria: Single-Center Experience in Uruguay |
| Q37294400 | Acute antibody-mediated rejection after lung transplantation |
| Q39105369 | Acute antibody-mediated rejection in kidney transplant recipients |
| Q38544529 | Advances in pharmacotherapy to treat kidney transplant rejection |
| Q39829568 | An Integrated View of Molecular Changes, Histopathology and Outcomes in Kidney Transplants |
| Q82213207 | Anti-Angiotensin Type 1 Receptor Antibodies Associated With Antibody Mediated Rejection in Donor HLA Antibody Negative Patients |
| Q37720377 | Antibodies to HLA Molecules Mimic Agonistic Stimulation to Trigger Vascular Cell Changes and Induce Allograft Injury |
| Q28076193 | Antibody Subclass Repertoire and Graft Outcome Following Solid Organ Transplantation |
| Q36296061 | Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients. |
| Q44425562 | Antibody-Mediated Rejection in Lung Transplantation: Clinical Outcomes and Donor-Specific Antibody Characteristics |
| Q37698860 | Antibody-Mediated Rejection: A Review |
| Q37904197 | Antibody-mediated allograft rejection: the emerging role of endothelial cell signalling and transcription factors. |
| Q38169496 | Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms. |
| Q39366396 | Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies |
| Q37969113 | Antibody-mediated rejection in heart transplantation: case presentation with a review of current international guidelines |
| Q35915453 | Antibody-mediated rejection in kidney transplantation: a review |
| Q38182527 | Antibody-mediated rejection in liver transplantation: current controversies and future directions |
| Q91251184 | Antibody-mediated rejection in the Banff classifications of 2007 and 2017: A comparison of renal graft loss prediction capability |
| Q38130585 | Antibody-mediated rejection, T cell-mediated rejection, and the injury-repair response: new insights from the Genome Canada studies of kidney transplant biopsies |
| Q52401610 | Antibody-mediated rejection: New approaches in prevention and management. |
| Q35876250 | Antibody-mediated rejection: an evolving entity in heart transplantation |
| Q27692014 | Antibody-mediated rejection: emergence of animal models to answer clinical questions |
| Q42553965 | Antibody-mediated rejection: pathogenesis, prevention, treatment, and outcomes |
| Q38062614 | Antibody-mediated vascular rejection of kidney allografts: a population-based study |
| Q44468613 | Antibody-mediated vascular rejection: relation to causation |
| Q34595998 | Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury |
| Q50876918 | B cell responses to allograft--more common than we thought? |
| Q38334458 | B-cell biomarkers in transplantation--from genes to therapy. |
| Q37058043 | Banff 2011 Meeting report: new concepts in antibody-mediated rejection |
| Q38510972 | Banff 2013 update: Pearls and pitfalls in transplant renal pathology |
| Q44180277 | Banff initiative for quality assurance in transplantation (BIFQUIT): reproducibility of C4d immunohistochemistry in kidney allografts |
| Q56967420 | Banff survey on antibody-mediated rejection clinical practices in kidney transplantation: Diagnostic misinterpretation has potential therapeutic implications |
| Q38059865 | Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update |
| Q43066994 | Below the waterline -- the danger of de novo donor-specific HLA antibodies |
| Q38282840 | Better understanding of transplant glomerulopathy secondary to chronic antibody-mediated rejection |
| Q39183148 | Biomarkers in solid organ transplantation: establishing personalized transplantation medicine |
| Q40417954 | C1q binding is not an independent risk factor for kidney allograft loss after an acute antibody-mediated rejection episode: a retrospective cohort study |
| Q37704862 | Capillary dilation and rarefaction are correlated with intracapillary inflammation in antibody-mediated rejection. |
| Q37778272 | Cardiac allograft vasculopathy: do adipocytes bridge alloimmune and metabolic risk factors? |
| Q38374793 | Chronic Antibody-Mediated Rejection in Nonhuman Primate Renal Allografts: Validation of Human Histological and Molecular Phenotypes. |
| Q37058050 | Chronic alloantibody mediated rejection |
| Q38309271 | Chronic allograft rejection: a fresh look. |
| Q86421426 | Chronic antibody-mediated rejection: new diagnostic tools - clinical significance of C4d deposition and improved detection and characterization of human leucocyte antigen antibodies |
| Q40967497 | Chronic rejection: Differences and similarities in various solid organ transplants |
| Q47574733 | Clinical and histopathologic features of antibody-mediated rejection among pediatric renal transplant recipients with preformed vs de novo donor-specific antibodies |
| Q39015291 | Clinical and immunological relevance of antibodies in solid organ transplantation |
| Q50802039 | Clinical and molecular significance of microvascular inflammation in transplant kidney biopsies. |
| Q37974480 | Clinical role of the renal transplant biopsy |
| Q39371134 | Complement in Kidney Transplantation |
| Q35655757 | Complement independent antibody-mediated endarteritis and transplant arteriopathy in mice |
| Q38226479 | Complement modulation in solid-organ transplantation. |
| Q26797336 | Computational Biology: Modeling Chronic Renal Allograft Injury |
| Q38795065 | Current pathological perspectives on chronic rejection in renal allografts |
| Q37882017 | Current problems of chronic active antibody-mediated rejection |
| Q38510977 | Currently available useful immunohistochemical markers of renal pathology for the diagnosis of renal allograft rejection |
| Q34427661 | Cytomegalovirus-responsive γδ T cells: novel effector cells in antibody-mediated kidney allograft microcirculation lesions |
| Q82082999 | De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection |
| Q47839666 | Defining the phenotype of antibody-mediated rejection in kidney transplantation: Advances in diagnosis of antibody injury |
| Q35027253 | Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. |
| Q34841849 | Diagnosis and management of antibody-mediated rejection: current status and novel approaches |
| Q34224452 | Diagnosis and prevention of chronic kidney allograft loss |
| Q41832267 | Diagnostic challenges in chronic antibody-mediated rejection |
| Q44944627 | Diagnostic criteria for kidney transplant rejection: a call to action |
| Q43116382 | Diagnostic significance of peritubular capillary basement membrane multilaminations in kidney allografts: old concepts revisited |
| Q42738129 | Dimensions of antibody-mediated rejection |
| Q39736122 | Early subclinical inflammation correlates with outcomes in positive crossmatch kidney allografts |
| Q45966400 | Early ultrastructural changes in renal allografts: correlation with antibody-mediated rejection and transplant glomerulopathy. |
| Q39512442 | Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial. |
| Q27027082 | Effector mechanisms of rejection |
| Q35124576 | Emerging role of B cells in chronic allograft dysfunction |
| Q37642331 | Endothelial Cells in Antibody-Mediated Rejection of Kidney Transplantation: Pathogenesis Mechanisms and Therapeutic Implications. |
| Q54983740 | Endothelial Dysfunction in Kidney Transplantation. |
| Q40806353 | Endothelial activation, lymphangiogenesis, and humoral rejection of kidney transplants |
| Q35550551 | Endothelial cell antibodies associated with novel targets and increased rejection |
| Q50582511 | Endothelial injury in transplant glomerulopathy is correlated with transcription factor T-bet expression. |
| Q89746966 | Evaluation and Treatment of Acute Rejection in Kidney Allografts |
| Q51292700 | Evidence for CD16a-Mediated NK Cell Stimulation in Antibody-Mediated Kidney Transplant Rejection. |
| Q58763181 | Fine needle aspirates of kidneys: a promising tool for RNA sequencing in native and transplanted kidneys |
| Q35541507 | Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis |
| Q41756397 | Genes associated with antibody-dependent cell activation are overexpressed in renal biopsies from patients with antibody-mediated rejection |
| Q34687190 | Genomic meta-analysis of growth factor and integrin pathways in chronic kidney transplant injury |
| Q37813407 | Genomics of chronic allograft injury |
| Q34534928 | Genotypic diversity of complement component C4 does not predict kidney transplant outcome |
| Q43065199 | Glomerular damage as a predictor of renal allograft loss |
| Q33392769 | Glomerular fibrin thrombi in ABO and crossmatch compatible renal allograft biopsies |
| Q40266578 | HLA Class II Antibody Activation of Endothelial Cells Promotes Th17 and Disrupts Regulatory T Lymphocyte Expansion |
| Q52373711 | HLA Class II-Triggered Signaling Cascades Cause Endothelial Cell Proliferation and Migration: Relevance to Antibody-Mediated Transplant Rejection. |
| Q89472835 | HLA in transplantation |
| Q35874401 | Heme Oxygenase-1 Inhibits HLA Class I Antibody-Dependent Endothelial Cell Activation |
| Q40278618 | Hepatic Infiltrates in Operational Tolerant Patients After Liver Transplantation Show Enrichment of Regulatory T Cells Before Proinflammatory Genes Are Downregulated |
| Q38154130 | Histopathological diagnosis of acute and chronic rejection in pediatric kidney transplantation |
| Q36612789 | Human leukocyte antigen antibody incompatible renal transplantation |
| Q33352583 | Humoral immunity in chronic allograft rejection: puzzle pieces come together |
| Q82599532 | IFNγ production by NK cells from HLA-sensitized patients after in vitro exposure to allo-antigens |
| Q37563822 | IMPROVING LONG-TERM OUTCOMES IN KIDNEY TRANSPLANTATION: TOWARDS A NEW PARADIGM OF POST-TRANSPLANT CARE IN THE UNITED STATES. |
| Q37813414 | Immune monitoring and biomarkers to predict chronic allograft dysfunction |
| Q34289043 | Immunological challenges of cardiac transplantation: the need for better animal models to answer current clinical questions |
| Q43150813 | Immunoproteasome beta subunit 10 is increased in chronic antibody-mediated rejection |
| Q37660263 | Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy |
| Q37375622 | Incidence and clinical significance of de novo donor specific antibodies after kidney transplantation |
| Q33661464 | Increased Circulating T Lymphocytes Expressing HLA-DR in Kidney Transplant Recipients with Microcirculation Inflammation. |
| Q53060554 | Increased intragraft rejection-associated gene transcripts in patients with donor-specific antibodies and normal biopsies. |
| Q64990670 | Innate networking: Thrombotic microangiopathy, the activation of coagulation and complement in the sensitized kidney transplant recipient. |
| Q53181446 | Interpreting NK cell transcripts versus T cell transcripts in renal transplant biopsies. |
| Q27023312 | Issues in solid-organ transplantation in children: translational research from bench to bedside. |
| Q38008362 | Key Features of the Intragraft Microenvironment that Determine Long-Term Survival Following Transplantation |
| Q46211382 | Kidney allograft survival after acute rejection, the value of follow-up biopsies |
| Q46322442 | Kidney intragraft donor-specific antibodies as determinant of antibody-mediated lesions and poor graft outcome |
| Q27006030 | Late and chronic antibody-mediated rejection: main barrier to long term graft survival |
| Q41834576 | Late kidney dysfunction in a kidney transplant recipient |
| Q54399816 | Long-term allograft tolerance is characterized by the accumulation of B cells exhibiting an inhibited profile. |
| Q43848201 | Long-term follow-up of non-HLA and anti-HLA antibodies: incidence and importance in renal transplantation |
| Q36417863 | Markers of Endothelial-to-Mesenchymal Transition: Evidence for Antibody-Endothelium Interaction during Antibody-Mediated Rejection in Kidney Recipients |
| Q44260404 | Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies. |
| Q39313174 | Modernization of Chronic Allograft Injury Research: Better Biomarkers, Better Studies, Better Outcomes. |
| Q48165787 | Molecular Assessment of Microcirculation Injury in Formalin-Fixed Human Cardiac Allograft Biopsies With Antibody-Mediated Rejection. |
| Q38877380 | Molecular assessment of disease states in kidney transplant biopsy samples |
| Q35629098 | Molecular classifiers for acute kidney transplant rejection in peripheral blood by whole genome gene expression profiling. |
| Q46363554 | Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies |
| Q39466553 | Molecular diagnosis of antibody-mediated rejection in human kidney transplants |
| Q39138227 | Molecular diagnostics in renal allograft biopsy interpretation: potential and pitfalls |
| Q34260097 | Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. |
| Q39001991 | Molecular nephropathology: ready for prime time? |
| Q37892320 | Molecular phenotypes of kidney graft rejection |
| Q37327986 | Molecular profiling of acute and chronic rejections of renal allografts |
| Q38676578 | Molecular targets on B-cells to prevent and treat antibody-mediated rejection in organ transplantation. Present and Future |
| Q41001433 | Multiplexed color-coded probe-based gene expression assessment for clinical molecular diagnostics in formalin-fixed paraffin-embedded human renal allograft tissue. |
| Q47175243 | Nanoparticle targeting to the endothelium during normothermic machine perfusion of human kidneys |
| Q37637948 | Noninvasive diagnosis of acute rejection of renal allografts |
| Q33395896 | Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy |
| Q36529421 | Pathological diagnosis of antibody-mediated rejection in renal allograft without c4d staining, how much reliable? |
| Q44608227 | Peritubular capillaritis in early renal allograft dysfunction is an indicator of acute rejection |
| Q84484568 | Peritubular capillary basement membrane changes in chronic renal allograft rejection: Comparison of light microscopic and ultrastructural observations |
| Q38005448 | Phenotypes of antibody-mediated rejection in organ transplants |
| Q36227374 | Plasma cell densities and glomerular filtration rates predict renal allograft outcomes following acute rejection. |
| Q35228522 | Platelets in early antibody-mediated rejection of renal transplants |
| Q49724104 | Polyomavirus BK Nephropathy-Associated Transcriptomic Signatures: A Critical Reevaluation |
| Q53242996 | Positive virtual crossmatch with negative flow crossmatch results in two cases. |
| Q59314345 | Precision Diagnostics in Transplantation: From Bench to Bedside |
| Q34534855 | Predominance of intraglomerular T-bet or GATA3 may determine mechanism of transplant rejection |
| Q53363804 | Presentation and Outcomes of C4d-Negative Antibody-Mediated Rejection After Kidney Transplantation. |
| Q30544649 | Pros and cons for C4d as a biomarker |
| Q37925104 | Proteasome inhibitor therapy for antibody-mediated rejection |
| Q49483423 | RNA expression profiling of nonhuman primate renal allograft rejection identifies tolerance. |
| Q36173541 | Rational clinical trial design for antibody mediated renal allograft injury. |
| Q47811161 | Re-evaluation of glomerulitis using occlusion criteria based on the Banff 2013 revision: a retrospective study |
| Q36314959 | Reassessing the Significance of Intimal Arteritis in Kidney Transplant Biopsy Specimens |
| Q35659332 | Recent advances in renal transplantation: antibody-mediated rejection takes center stage |
| Q38544617 | Relationship among C1q-fixing de novo donor specific antibodies, C4d deposition and renal outcome in transplant glomerulopathy. |
| Q42582852 | Renal allograft rejection: pieces of the puzzle |
| Q33407913 | Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy |
| Q37313051 | Report from a consensus conference on antibody-mediated rejection in heart transplantation |
| Q38772536 | Reviewing the pathogenesis of antibody-mediated rejection and renal graft pathology after kidney transplantation |
| Q38168615 | Rituximab is associated with improved survival in cardiac allograft patients with antibody-mediated rejection: a single center review. |
| Q26864255 | Role of complement and NK cells in antibody mediated rejection |
| Q50507367 | Significance of C4d deposition in antibody-mediated rejection. |
| Q89449672 | Single-Cell Transcriptomics of a Human Kidney Allograft Biopsy Specimen Defines a Diverse Inflammatory Response |
| Q91028577 | Sox7 is involved in antibody-dependent endothelial cell activation and renal allograft injury via the Jagged1-Notch1 pathway |
| Q42598786 | Summary of FDA antibody-mediated rejection workshop |
| Q30276752 | Systems Biology in Kidney Transplantation: The Application of Multi-Omics to a Complex Model |
| Q53241382 | The 20S proteasome core, active within apoptotic exosome-like vesicles, induces autoantibody production and accelerates rejection. |
| Q42174325 | The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology. |
| Q38676925 | The Revised (2013) Banff Classification for Antibody-Mediated Rejection of Renal Allografts: Update, Difficulties, and Future Considerations |
| Q38793606 | The XIIIth Banff Conference on Allograft Pathology: The Banff 2015 Heart Meeting Report: Improving Antibody-Mediated Rejection Diagnostics: Strengths, Unmet Needs, and Future Directions |
| Q37359074 | The clinical and genomic significance of donor-specific antibody-positive/C4d-negative and donor-specific antibody-negative/C4d-negative transplant glomerulopathy |
| Q39010381 | The critical role of Krüppel-like factors in kidney disease |
| Q37286247 | The diagnostic value of transcription factors T-bet/GATA3 ratio in predicting antibody-mediated rejection. |
| Q34106158 | The generation and maintenance of serum alloantibody. |
| Q40882063 | The impact of C4d-negative acute antibody-mediated rejection on short-term prognosis among kidney transplant recipients |
| Q38003049 | The impact of donor-specific anti-HLA antibodies on late kidney allograft failure |
| Q27021227 | The importance of C4d in biopsies of kidney transplant recipients |
| Q44940147 | The interplay of donor-specific antibodies, allograft C4d deposition, and antibody-mediated rejection |
| Q41196219 | The molecular landscape of antibody-mediated kidney transplant rejection: evidence for NK involvement through CD16a Fc receptors |
| Q39812222 | The molecular phenotype of 6-week protocol biopsies from human renal allografts: reflections of prior injury but not future course. |
| Q37813404 | The pathology of chronic allograft dysfunction |
| Q26862195 | The perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejection |
| Q54116671 | The prognostic values of caveolin-1 immunoreactivity in peritubular capillaries in patients with kidney transplantation. |
| Q38048605 | The role of complement in antibody-mediated rejection in kidney transplantation |
| Q38151921 | The specificity of acute and chronic microvascular alterations in renal allografts |
| Q43507137 | Three-year outcome of isolated glomerulitis on 3-month protocol biopsies of donor HLA antibody negative patients |
| Q38237365 | Through a glass darkly: seeking clarity in preventing late kidney transplant failure |
| Q90663092 | Transcriptome Analysis in Renal Transplant Biopsies Not Fulfilling Rejection Criteria |
| Q38436456 | Translational implications of endothelial cell dysfunction in association with chronic allograft rejection. |
| Q21999478 | Transplant biopsy beyond light microscopy |
| Q55054954 | Transplant glomerulopathy: it's not always about chronic rejection. |
| Q38205229 | Transplant glomerulopathy: the interaction of HLA antibodies and endothelium |
| Q88092508 | Transplantation: Molecular diagnosis of kidney transplant rejection |
| Q37052024 | Tubuloreticular Inclusions in Renal Allografts Associate with Viral Infections and Donor-Specific Antibodies |
| Q99604948 | Urinary Biomarkers for Diagnosis and Prediction of Acute Kidney Allograft Rejection: A Systematic Review |
| Q36684948 | VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients |
| Q34761349 | What's new in clinical solid organ transplantation by 2013. |
| Q85417822 | What's new in renal and pancreatic transplantation in 2011? |
Search more.